Literature DB >> 27684194

Ferric Chloride-induced Murine Thrombosis Models.

Wei Li1, Marvin Nieman2, Anirban Sen Gupta3.   

Abstract

Arterial thrombosis (blood clot) is a common complication of many systemic diseases associated with chronic inflammation, including atherosclerosis, diabetes, obesity, cancer and chronic autoimmune rheumatologic disorders. Thrombi are the cause of most heart attacks, strokes and extremity loss, making thrombosis an extremely important public health problem. Since these thrombi stem from inappropriate platelet activation and subsequent coagulation, targeting these systems therapeutically has important clinical significance for developing safer treatments. Due to the complexities of the hemostatic system, in vitro experiments cannot replicate the blood-to-vessel wall interactions; therefore, in vivo studies are critical to understand pathological mechanisms of thrombus formation. To this end, various thrombosis models have been developed in mice. Among them, ferric chloride (FeCl3) induced vascular injury is a widely used model of occlusive thrombosis that reports platelet activation and aggregation in the context of an aseptic closed vascular system. This model is based on redox-induced endothelial cell injury, which is simple and sensitive to both anticoagulant and anti-platelets drugs. The time required for the development of a thrombus that occludes blood flow gives a quantitative measure of vascular injury, platelet activation and aggregation that is relevant to thrombotic diseases. We have significantly refined this FeCl3-induced vascular thrombosis model, which makes the data highly reproducible with minimal variation. Here we describe the model and present representative data from several experimental set-ups that demonstrate the utility of this model in thrombosis research.

Entities:  

Mesh:

Year:  2016        PMID: 27684194      PMCID: PMC5091988          DOI: 10.3791/54479

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  42 in total

1.  Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa.

Authors:  R J Leadley; S R Morgan; R Bentley; J S Bostwick; C J Kasiewski; C Heran; V Chu; K Brown; P Moxey; W R Ewing; H Pauls; A P Spada; M H Perrone; C T Dunwiddie
Journal:  J Cardiovasc Pharmacol       Date:  1999-12       Impact factor: 3.105

2.  Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice.

Authors:  S Konstantinides; K Schäfer; T Thinnes; D J Loskutoff
Journal:  Circulation       Date:  2001-01-30       Impact factor: 29.690

3.  Mechanisms underlying FeCl3-induced arterial thrombosis.

Authors:  A Eckly; B Hechler; M Freund; M Zerr; J-P Cazenave; F Lanza; P H Mangin; C Gachet
Journal:  J Thromb Haemost       Date:  2011-04       Impact factor: 5.824

4.  Distinct antithrombotic consequences of platelet glycoprotein Ibalpha and VI deficiency in a mouse model of arterial thrombosis.

Authors:  S Konstantinides; J Ware; P Marchese; F Almus-Jacobs; D J Loskutoff; Z M Ruggeri
Journal:  J Thromb Haemost       Date:  2006-09       Impact factor: 5.824

5.  Heteromultivalent liposomal nanoconstructs for enhanced targeting and shear-stable binding to active platelets for site-selective vascular drug delivery.

Authors:  Christa L Modery; Madhumitha Ravikumar; Timothy L Wong; Michael J Dzuricky; Nat Durongkaveroj; Anirban Sen Gupta
Journal:  Biomaterials       Date:  2011-09-08       Impact factor: 12.479

6.  Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis.

Authors:  E Marsh Lyle; S D Lewis; E D Lehman; S J Gardell; S L Motzel; J J Lynch
Journal:  Thromb Haemost       Date:  1998-03       Impact factor: 5.249

Review 7.  Mechanisms of cell signaling by the scavenger receptor CD36: implications in atherosclerosis and thrombosis.

Authors:  Roy L Silverstein; Wei Li; Young Mi Park; S Ohidar Rahaman
Journal:  Trans Am Clin Climatol Assoc       Date:  2010

8.  Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice.

Authors:  Arunima Ghosh; Wei Li; Maria Febbraio; Ricardo G Espinola; Keith R McCrae; Erin Cockrell; Roy L Silverstein
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

Review 9.  Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptoms.

Authors:  Steven R Levine; Pooja Khatri; Joseph P Broderick; James C Grotta; Scott E Kasner; Doojin Kim; Brett C Meyer; Peter Panagos; Jose Romano; Phillip Scott
Journal:  Stroke       Date:  2013-07-11       Impact factor: 7.914

Review 10.  Platelet adhesion under flow.

Authors:  Zaverio M Ruggeri
Journal:  Microcirculation       Date:  2009-01       Impact factor: 2.628

View more
  23 in total

1.  Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis.

Authors:  Christa L Pawlowski; Wei Li; Michael Sun; Kavya Ravichandran; DaShawn Hickman; Clarissa Kos; Gurbani Kaur; Anirban Sen Gupta
Journal:  Biomaterials       Date:  2017-03-14       Impact factor: 12.479

2.  The role of type 1 interferons in coagulation induced by gram-negative bacteria.

Authors:  Xinyu Yang; Xiaoye Cheng; Yiting Tang; Xianhui Qiu; Zhongtai Wang; Guang Fu; Jianfeng Wu; Haixia Kang; Jing Wang; Haichao Wang; Fangping Chen; Xianzhong Xiao; Timothy R Billiar; Ben Lu
Journal:  Blood       Date:  2020-04-02       Impact factor: 22.113

3.  Platelet CD36 promotes thrombosis by activating redox sensor ERK5 in hyperlipidemic conditions.

Authors:  Moua Yang; Brian C Cooley; Wei Li; Yiliang Chen; Jeannette Vasquez-Vivar; Na'il O Scoggins; Scott J Cameron; Craig N Morrell; Roy L Silverstein
Journal:  Blood       Date:  2017-03-23       Impact factor: 22.113

Review 4.  Thymidine phosphorylase: A potential new target for treating cardiovascular disease.

Authors:  Wei Li; Hong Yue
Journal:  Trends Cardiovasc Med       Date:  2017-10-20       Impact factor: 6.677

5.  VE-1902-A direct thrombin inhibitor with reversible covalent mechanism of action shows efficacy with reduced bleeding in rodent models of thrombosis.

Authors:  Mohanram Sivaraja; Daniel M Clemens; Sivan Sizikov; Subhadra Dash; Chengpei Xu; Matthew Rienzo; Bo Yang; Molly Ryan; Madhuri Chattopadhyay; Lev Igoudin; Stephanie S Chang; Samuel Keutzer; Piotr Zalicki; M Angels Estiarte; Timothy P Shiau; Kevin M Short; David C Williams; Anirban Datta; Nicola Pozzi; Enrico Di Cera; C Michael Gibson; Keith A A Fox; David B Kita
Journal:  Thromb Res       Date:  2020-04-19       Impact factor: 3.944

6.  Near-infrared Fluorophores for Thrombosis Diagnosis and Therapy.

Authors:  Bin Sun; Kenneth S Hettie; Shoujun Zhu
Journal:  Adv Ther (Weinh)       Date:  2021-02-15

7.  Targeting Thymidine Phosphorylase With Tipiracil Hydrochloride Attenuates Thrombosis Without Increasing Risk of Bleeding in Mice.

Authors:  Adam Belcher; Abu Hasanat Md Zulfiker; Oliver Qiyue Li; Hong Yue; Anirban Sen Gupta; Wei Li
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-10       Impact factor: 8.311

8.  Combination targeting of 'platelets + fibrin' enhances clot anchorage efficiency of nanoparticles for vascular drug delivery.

Authors:  Michael Sun; Kenji Miyazawa; Tejal Pendekanti; Amaya Razmi; Emre Firlar; Stephanie Yang; Tolou Shokuhfar; Oliver Li; Wei Li; Anirban Sen Gupta
Journal:  Nanoscale       Date:  2020-10-16       Impact factor: 7.790

9.  The Combination of Tissue-Engineered Blood Vessel Constructs and Parallel Flow Chamber Provides a Potential Alternative to In Vivo Drug Testing Models.

Authors:  Wanjiku Njoroge; Andrea C Hernández Hernández; Faiza Idris Musa; Robert Butler; Alan G S Harper; Ying Yang
Journal:  Pharmaceutics       Date:  2021-03-05       Impact factor: 6.321

Review 10.  Understanding the Pathophysiology of Thrombotic APS through Animal Models.

Authors:  Alex A Gandhi; Shanea K Estes; Christine E Rysenga; Jason S Knight
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.